Skip to main content
. Author manuscript; available in PMC: 2013 Aug 12.
Published in final edited form as: Adv Pharmacol. 2012;64:303–325. doi: 10.1016/B978-0-12-394816-8.00009-X

FIGURE 2. Role of STEP in Alzheimer’s disease.

FIGURE 2

In Alzheimer’s disease, Aβ-oligomers activate STEP by two parallel pathways. (1) Aβ-oligomers bind to α7-nicotinic receptors and cause calcinuerin-dependent dephosphorylation of STEP at its KIM domain (2) Aβ-oligomers block the proteasome-mediated degradation of STEP and increase STEP levels. Both these events lead to increase in STEP function and increased endocytosis of NMDA and AMPA receptors causing cognitive dysfunction.